Senderra Specialty Pharmacy has introduced EBGLYSS™, Lilly’s primary biologic treatment for moderate-to-severe atopic dermatitis, to its SenderraCare+ platform. This initiative aims to revolutionize specialty therapy by integrating enrollment, adherence support, and medication management into a user-friendly, real-time digital system. By streamlining treatment initiation, boosting patient compliance, reducing abandonment rates, and providing actionable insights, SenderraCare+ offers patients and healthcare providers a seamless and high-quality care experience.
The addition of EBGLYSS to SenderraCare+ signifies a significant advancement in patient-focused specialty care. Patients dealing with moderate-to-severe atopic dermatitis, who have not responded well to topical therapies or cannot use them, now have access to a comprehensive digital solution that offers real-time updates on their medication status and facilitates two-way communication throughout the treatment process. This innovative approach, accessible via mobile devices or desktops, aligns with Senderra’s commitment to enhancing the specialty medication journey for all patients.
One of the primary advantages of SenderraCare+ is its ability to expedite the onboarding process for patients, enabling them to commence their medication promptly after leaving their healthcare provider’s office. Through digital SMS enrollment and prescheduled welcome calls with the patient care team, patients can swiftly navigate the consent process, provide necessary information, and schedule medication deliveries and refills. Moreover, the platform empowers patients to request live consultations from pharmacists or nurses, enhancing their engagement and control over their treatment journey.
The benefits of SenderraCare+ extend beyond patients to healthcare providers, who benefit from streamlined prior authorization services for patient prescriptions. By automating enrollment in SenderraCare+ upon prescription submission, healthcare professionals can save time and ensure a seamless process for patients to initiate therapy. This high-touch service model not only enhances provider-patient interactions but also fosters efficient communication and collaboration throughout the patient’s treatment journey.
Senderra Specialty Pharmacy’s commitment to patient care is evident in its innovative technology solutions, specialized patient care teams, and strong partnerships with prescribers, pharmaceutical manufacturers, and payers. The company’s dedication to improving healthcare experiences for patients with complex medical conditions underscores its mission to provide comprehensive support and clinical expertise. Through SenderraCare+ and the integration of EBGLYSS, Senderra continues to set new standards in specialty pharmacy services, prioritizing patient empowerment and engagement.
Key Takeaways:
– Senderra Specialty Pharmacy’s SenderraCare+ platform integrates EBGLYSS™ to enhance the digital patient experience for those with moderate-to-severe atopic dermatitis.
– The platform accelerates treatment initiation, improves medication adherence, and reduces patient abandonment rates through real-time updates and interactive features.
– Healthcare providers benefit from streamlined prior authorization services and automated patient enrollment, freeing up time and ensuring a seamless therapy initiation process.
– Senderra’s commitment to patient care, technological innovation, and strong partnerships underscores its mission to provide exceptional support and clinical expertise in specialty pharmacy services.
Read more on finance.yahoo.com